(Q44573927)

4 December 2017

title

Rapid enzymatic test for phenotypic HIV protease drug resistance (English)

1 reference

4 December 2017

Dieter Hoffmann

1

1 reference

4 December 2017

Irmgard Assfalg-Machleidt

2

1 reference

4 December 2017

Hans Nitschko

3

1 reference

4 December 2017

Klaus von der Helm

4

1 reference

4 December 2017

Ulrich Koszinowski

5

1 reference

4 December 2017

Werner Machleidt

6

1 reference

4 December 2017

publication date

1 July 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

384

1 reference

4 December 2017

issue

7

1 reference

4 December 2017

page(s)

1109-1117

1 reference

The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

HIV genotype and phenotype--arresting resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Fluorescence-based continuous assay for the aspartyl protease of human immunodeficiency virus-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Testing for HIV-1 drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Clinical utility of testing human immunodeficiency virus for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Synthetic approaches to continuous assays of retroviral proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

International perspectives on antiretroviral resistance. Resistance to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Increasing prevalence of resistance mutations in antiretroviral-naïve individuals with established HIV-1 infection from 1996-2001 in St. Louis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Technologies for measuring HIV-1 drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Identification, purification, and cell culture assays of retroviral proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2003.124

21 January 2018

Identifiers

DOI

10.1515/BC.2003.124

1 reference

release_mc7i23mfzrbplpirne6tyq2gqa

4 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mc7i23mfzrbplpirne6tyq2gqa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference